News

Ab Studio designed antibodies are at clinical stages! GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody designed by Ab Studio shows promising new results published in ASH's annual meeting.   Click here for more information.

|

Using our proven technology of computer-design and on-bench validation, SEND US YOUR PROTEIN SEQUENCE and we will provide a drug candidate OFFERING IMPROVED BALANCE OF SAFETY, EFFICACY, AND MANUFACTURABILITY.  

Resources

Publications

Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action

Read More

A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies

Read More

Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity

Read More

Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2

Read More

First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants

Read More

Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response

Read More

Abstract LB067: Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy

Read More

Optimization of therapeutic antibodies

Read More

Antibody humanization and optimization, Art of safety efficacy and manufacture-ability balance

Watch Now

Pre-humanized VHH phage library-Save 6-8 months for antibody discovery

Watch Now

3541 Investment Blvd. Suite 3,
Hayward, CA 94545 USA